Important note

This AI stock analysis for Pfizer is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Pfizer - AI Stock Analysis

Analysis generated January 28, 2025

Pfizer Inc. is a global biopharmaceutical company headquartered in New York City. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Pfizer is known for its rigorous R&D efforts, bringing innovative treatments to market and maintaining a strong portfolio of blockbuster drugs. Its global reach and well-established brand have made it a household name in the pharmaceutical industry.

Fundamental Analysis

The recent financial data for Pfizer shows impressive growth. The revenue for the last quarter was $17.7 billion, representing a 33.27% increase compared to the previous quarter and a 31.21% increase year over year. This substantial growth in revenue highlights strong performance and market demand for Pfizer's products.

The net income for the last quarter was $4.47 billion, an astonishing increase of 10,790.24% compared to the previous quarter and 287.45% compared to the same quarter last year. This surge in net income is attributed to increased sales and possibly cost control measures.

EBITDA for the last quarter stood at $6.78 billion, marking a 241.66% increase from the previous quarter and a 567.40% rise compared to the same quarter last year. EBITDA is an essential measure of a company's operational performance, and these numbers suggest strong profitability and operational efficiency.

However, Pfizer's current P/E ratio is 34.79, which could be considered high. A high P/E ratio might indicate that the stock is overvalued, potentially signaling a bearish outlook for investors who are cautious about valuation.

Technical Analysis

The current stock price of Pfizer is $26.72, marking an increase of 0.38% from a month ago and 1.60% from a year ago. This suggests a positive short-term and long-term trend in stock price. The trend appears bullish.

The current Simple Moving Average (SMA10) is 26.35, up from the previous SMA10 of 26.31. This rise in SMA10 indicates a potential upward trend in price movement, supporting the bullish trend observed.

The Relative Strength Index (RSI) is at 53.5, indicating a neutral condition. RSI values between 30 and 70 are considered neutral, suggesting that the stock is neither overbought nor oversold at the moment.

Alternative Data Analysis

Analyzing alternative data reveals some concerns. Pfizer has 546 open positions, a 24% decrease in the last couple of months. This reduction could indicate the company is making efforts to improve margins or cut costs, which is not a great sign for a growing company.

The company's business outlook among employees is reported as neutral, potentially reflecting internal sentiments that are neither overly positive nor negative.

In terms of customer acquisition, Pfizer's website has experienced a 13% decline in visitors, currently estimated at 1.5 million. This trend could be worrying as it potentially indicates a loss in customer interest.

Customer engagement metrics show that Pfizer has 120,000 followers on Instagram and 480,000 followers on Twitter. The number of followers on Instagram has remained flat, while Twitter followers have slightly declined by 1%. This stagnation and slight decrease in social media engagement may also indicate waning interest in the company.

Additionally, AltIndex's AI score for Pfizer is 38, which is a sell signal. This score aggregates fundamental, technical, and alternative data analysis to provide an outlook on the stock's performance.

Conclusion

In conclusion, Pfizer has demonstrated strong financial performance with significant increases in revenue, net income, and EBITDA. The company's stock shows a positive trend in both short-term and long-term price movements. However, the high P/E ratio may indicate overvaluation, and the alternative data analysis reveals some concerns regarding employee sentiment, customer acquisition, and engagement.

Considering all the data, Pfizer is currently performing well financially, but there are red flags in alternative data that warrant a cautious approach. Investors should keep an eye on these trends and consider them when making investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.